Ionis Pharmaceuticals Inc (IONS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$58.09-0.07%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IONS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||||||
| Revenues | 874.1 | 943.7 | 705.1 | 787.6 | 587.4 | 810.5 | 729.3 | 1,122.6 | 599.7 | 507.7 | 346.6 | 283.7 | 214.2 | 147.3 | 102.0 | 99.1 | 108.5 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 507.7 | 346.6 | 283.7 | 214.2 | 147.3 | 102.0 | 99.1 | 108.5 |
| Cost of Revenues | 16.0 | 15.9 | 11.2 | 9.1 | 14.1 | 10.8 | 11.9 | 4.4 | 1.8 | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | |||||||||||||||||
| Selling, General & Admin | 527.8 | 393.9 | 267.5 | 232.6 | 150.3 | 186.3 | 354.3 | 286.6 | 244.6 | 108.5 | — | — | — | — | — | — | — |
| R&D Expenses | — | 915.6 | — | 899.6 | — | 638.2 | 531.0 | 461.5 | 411.9 | 372.5 | 340.4 | 319.5 | 238.9 | 173.7 | 154.6 | 153.1 | 145.2 |
| Operating Income | (594.4) | (381.7) | (475.1) | (353.7) | (410.2) | (30.2) | (172.1) | 365.9 | (61.4) | 31.0 | (20.2) | (75.8) | (47.7) | (51.7) | (68.9) | (71.1) | (48.4) |
| Earnings from Continuing Operations | |||||||||||||||||
| Interest Expense | 18.8 | 17.3 | 17.0 | 12.7 | 8.1 | 9.3 | 9.5 | 12.4 | 44.8 | 44.8 | 38.8 | 36.7 | 22.2 | 19.4 | 21.2 | 16.7 | 13.2 |
| Asset Writedown | — | — | — | — | — | — | — | 2.2 | 0.8 | 0.8 | 2.3 | 1.9 | — | — | — | — | — |
| EBT, Incl. Unusual Items | (562.0) | (379.6) | (460.1) | (334.0) | (258.0) | (29.1) | (170.0) | 346.8 | (76.2) | (16.8) | (83.6) | (87.9) | (54.4) | (66.6) | (74.6) | (84.8) | — |
| Income Tax Expense | 3.2 | 1.8 | (6.2) | 32.3 | 11.7 | (0.6) | 345.2 | 51.5 | (291.1) | (6.0) | 2.9 | 0.4 | (15.4) | — | — | 0.0 | 0.1 |
| Earnings from Continuing Operations | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (84.8) | (61.3) |
| Net Income | |||||||||||||||||
| Minority Interest | — | — | — | — | 0.0 | 0.0 | (35.5) | 9.1 | (58.8) | (11.1) | — | — | — | — | — | (4.4) | (4.4) |
| Net Income | (565.2) | (381.4) | (453.9) | (366.3) | (269.7) | (28.6) | (444.3) | 278.1 | 273.7 | 0.3 | (60.4) | (88.3) | (39.0) | (60.6) | (65.5) | (84.8) | (61.3) |
| Per Share | |||||||||||||||||
| Basic EPS | (3.42) | (2.38) | (3.04) | (2.56) | (1.90) | (0.20) | (3.18) | 2.00 | 2.09 | 0.15 | — | — | — | — | — | (0.85) | (0.62) |
| Diluted EPS | (3.42) | (2.38) | (3.04) | (2.56) | (1.90) | (0.20) | (3.18) | 1.90 | 2.07 | 0.15 | — | — | — | — | — | (0.85) | (0.62) |
| Revenue per Share | 5.28 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 165.4 | 160.0 | 149.5 | 143.2 | 141.8 | 141.0 | 139.6 | 140.0 | 132.3 | 124.0 | — | — | — | 110.5 | 100.6 | 99.7 | 99.1 |
| Diluted Weighted Avg Shares | 165.4 | 160.0 | 149.5 | 143.2 | 141.8 | 141.0 | 139.6 | 153.2 | 134.1 | 126.1 | — | — | — | 110.5 | 100.6 | 99.7 | 99.1 |
| Supplemental | |||||||||||||||||
| EBIT | (594.4) | (381.7) | (475.1) | (353.7) | (410.2) | (30.2) | (172.1) | 365.9 | (61.4) | 31.0 | (20.2) | (75.8) | (47.7) | (51.7) | (68.9) | (71.1) | (48.4) |
| Effective Tax Rate | -0.6% | — | — | -9.7% | -4.5% | 1.9% | -203.0% | 14.9% | 382.3% | 35.7% | -3.5% | -0.4% | 28.3% | — | — | -0.0% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.